INKT

MiNK Therapeutics, Inc.

Insider Trades

NameValueActionPriceCurrent Price
Ryan BarbaraDirector
$13k1k shares
SellJun 4, 2026
$12.80
--
Ryan BarbaraDirector
$6.3k500 shares
SellJun 4, 2026
$12.68
--
Ryan BarbaraDirector
$4.6k300 shares
SellMar 10, 2026
$15.28
--
Ryan BarbaraDirector
$7.8k500 shares
SellMar 10, 2026
$15.57
--
Ryan BarbaraDirector
$7.7k500 shares
SellMar 10, 2026
$15.30
--
Ryan BarbaraDirector
$2.0k200 shares
SellMar 9, 2026
$10.17
--

News

globenewswire.comMiNK Therapeutics Announces its Virtual 2026 Annual Shareholders Meetingglobenewswire.comJun 3globenewswire.comMiNK Therapeutics Announces First Patient Dosed in Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illnessglobenewswire.comMay 28globenewswire.comMiNK Therapeutics Reports New Data on agenT-797, an allo-iNKT Cell Therapy at ATS 2026; Simultaneously Published in Clinical Immunology Communicationsglobenewswire.comMay 20seekingalpha.comMiNK Therapeutics, Inc. (INKT) Q1 2026 Earnings Call Transcriptseekingalpha.comMay 15marketbeat.comMiNK Therapeutics Q1 Earnings Call Highlightsmarketbeat.comMay 15